Mainz Biomed Secures $3 Million in Funding Through Securities Purchase Agreement

Mainz Biomed has secured $3 million through a securities purchase agreement with an institutional investor. The agreement involved the sale of 2,222,222 pre-funded units, and the offering closed on August 5, 2025. The stock has a Buy rating with a $14.00 price target and a neutral overall stock score due to financial performance challenges and bearish momentum.

Mainz Biomed N.V. (NASDAQ: MYNZ), a molecular genetics diagnostic company specializing in early cancer detection, has successfully raised approximately $3.0 million through a follow-on offering of 2,222,222 units. Each unit consists of one ordinary share (or pre-funded warrant in lieu thereof) and one Series A warrant to purchase one and one half ordinary shares. The offering closed on August 5, 2025, with each unit sold at an effective offering price of $1.35. Each Series A warrant is immediately exercisable at an exercise price of $1.35 per share and will expire five years from the date of issuance.

Maxim Group LLC acted as the sole placement agent for the offering, which was conducted pursuant to a registration statement on Form F-1, as amended (File No. 333-289095). The registration statement was declared effective by the Securities and Exchange Commission (SEC) on August 4, 2025. The offering is only being made through a prospectus, which is part of the Registration Statement. Copies of the final prospectus may be obtained from Maxim Group LLC.

Mainz Biomed's flagship product, ColoAlert®, is an accurate, non-invasive early-detection diagnostic test for colorectal cancer, marketed across Europe. The company is currently running a clinical study to prepare for its pivotal FDA clinical study and US regulatory approval. Additionally, Mainz Biomed's product candidate portfolio includes PancAlert, an early-stage pancreatic cancer screening test based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples.

The stock has been given a Buy rating with a $14.00 price target and a neutral overall stock score, primarily due to financial performance challenges and bearish momentum.

References:
[1] https://mainzbiomed.com/mainz-biomed-announces-pricing-of-3-0-million-follow-on-offering-of-ordinary-shares-and-warrants/
[2] https://www.biospace.com/press-releases/mainz-biomed-announces-pricing-of-3-0-million-follow-on-offering-of-ordinary-shares-and-warrants